NBC Securities Inc. Grows Position in Grifols, S.A. (NASDAQ:GRFS)

NBC Securities Inc. grew its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 112,543.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,448 shares of the biotechnology company's stock after purchasing an additional 57,397 shares during the period. NBC Securities Inc.'s holdings in Grifols were worth $408,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Capital World Investors lifted its stake in Grifols by 0.7% during the 4th quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock worth $157,239,000 after acquiring an additional 154,358 shares in the last quarter. Brandes Investment Partners LP lifted its stake in Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock worth $152,491,000 after acquiring an additional 592,096 shares in the last quarter. Black Creek Investment Management Inc. lifted its stake in Grifols by 1.3% during the 4th quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company's stock worth $83,715,000 after acquiring an additional 141,615 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in Grifols by 46.1% during the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock worth $49,144,000 after acquiring an additional 2,083,722 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Grifols by 11.9% during the 4th quarter. Janus Henderson Group PLC now owns 3,045,260 shares of the biotechnology company's stock worth $22,642,000 after acquiring an additional 324,869 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GRFS. Morgan Stanley started coverage on Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating on the stock. Wall Street Zen upgraded Grifols from a "hold" rating to a "buy" rating in a report on Friday, May 23rd.

Grifols Stock Up 1.1%

Shares of GRFS traded up $0.10 during mid-day trading on Friday, reaching $8.82. The company's stock had a trading volume of 530,798 shares, compared to its average volume of 1,163,746. Grifols, S.A. has a 12-month low of $5.79 and a 12-month high of $9.96. The stock has a market cap of $6.06 billion, a PE ratio of 7.54 and a beta of 0.53. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The company's 50 day moving average is $7.44 and its 200 day moving average is $7.55.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.